NUTM2B: A Potential Drug Target and Biomarker (G729262)

Target Name: NUTM2B

NCBI ID: G729262

NUTM2B

NUTM2B: A Potential Drug Target and Biomarker

NUTM2B, also known as FAM22B, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. NUTM2B is a key regulator of the microRNA (miRNA) pathway, a critical pathway that regulates gene expression and has been implicated in a wide range of biological processes, including cancer, neurodegenerative diseases, and autoimmune disorders.

NUTM2B is a highly conserved non-coding RNA molecule that is expressed in a variety of tissues and cell types. It is composed of 21 amino acid residues and has a predicted localization to the nuclear matrix. NUTM2B is well-studied in the context of miRNA pathways, and has been shown to play a critical role in regulating miRNA expression levels.

NUTM2B has been shown to interact with several key players in the miRNA pathway, including miR-202, a well-known regulator of the miRNA pathway that is itself involved in the regulation of many cellular processes, including cell growth, apoptosis, and inflammation. NUTM2B has also been shown to interact with the protein JKR2, which is involved in the regulation of microRNA stability and translation efficiency.

In addition to its role in the miRNA pathway, NUTM2B has also been shown to play a critical role in the regulation of cellular processes that are relevant to many diseases, including cancer. For example, NUTM2B has been shown to promote the growth and survival of cancer cells, and has been identified as a potential therapeutic target for cancer treatment.

NUTM2B has also been shown to play a role in the regulation of cellular processes that are relevant to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. For example, NUTM2B has been shown to promote the development of neurodegenerate diseases, and has been identified as a potential therapeutic target for these diseases.

In addition to its role in the regulation of cellular processes, NUTM2B has also been shown to play a critical role in the regulation of the immune system. For example, NUTM2B has been shown to promote the development of immune cells that are involved in cancer surveillance, and has been identified as a potential therapeutic target for cancer immunotherapy.

Overall, NUTM2B is a highly promising drug target and biomarker due to its role in the regulation of the miRNA pathway and its potential involvement in a wide range of diseases. Further research is needed to fully understand the mechanisms of NUTM2B's role in these diseases and to develop effective therapies based on this knowledge.

Protein Name: NUT Family Member 2B

The "NUTM2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUTM2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets